Theranostics Health – Advancing Personalized Medicine Through Proteomics

Theranostics Health is a leading provider of proteomic services whose resources and capabilities offer unique opportunities for pursuing protein-based biomarker discovery or translational research strategies. These core technologies center upon the Reverse-phase Protein Microarray (RPMA) and Laser Capture Microdissection (LCM) platforms. Theranostics Health’s technologies are of particular value for biomarker efforts involving Molecular Targeted Therapies, and allow for insights into the phospho-activation status of drug targets and receptors, their downstream signal transduction pathways, as well as potential survival or adaptive mechanisms within targeted cell populations.

The RPMA platform is a flexible, protein lysate array that allows for the simultaneous analysis of hundreds of clinical or experimental samples in the presence of protein or peptide calibration standards. The RPMA assay’s sensitivity allows for the measurement of analytes of interest from picogram to attogram amounts of protein lysates. Currently, several hundred assays are available that target surface receptors, intracellular signaling pathways, transcriptional factors, nuclear proteins, etc.

The LCM can confer the specificity of immunohistochemistry staining to the RPMA platform by selectively capturing specific cells of interest (e.g. tumor, stromal, epidermal cells, etc.). At Theranostics Health, pathology-directed LCM services are available for liquid nitrogen frozen and FFPE-prepared tissues, as well as for excised tissue samples and core needle biopsies.

Together, or individually, these technologies allow for drug development companies to create an integrated proteomic biomarker development program from early discovery and screening involving cell culture studies through to analysis of human clinical samples.